MX2013007737A - Fibra y probioticos para reducir sintomas intestinales relacionados con estres. - Google Patents

Fibra y probioticos para reducir sintomas intestinales relacionados con estres.

Info

Publication number
MX2013007737A
MX2013007737A MX2013007737A MX2013007737A MX2013007737A MX 2013007737 A MX2013007737 A MX 2013007737A MX 2013007737 A MX2013007737 A MX 2013007737A MX 2013007737 A MX2013007737 A MX 2013007737A MX 2013007737 A MX2013007737 A MX 2013007737A
Authority
MX
Mexico
Prior art keywords
stress
fiber
probiotics
symptoms related
intestinal symptoms
Prior art date
Application number
MX2013007737A
Other languages
English (en)
Inventor
Magali Faure
Gabriela Bergonzelli Degonda
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013007737A publication Critical patent/MX2013007737A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención proporciona una composición que es adecuada para reducir el impacto de estrés crónico en síntomas y/o condiciones intestinales. La composición comprende un microorganismo probiótico y fibra soluble. De preferencia, la fibra soluble es una fibra soluble de baja viscosidad. La composición es en particular adecuada para aliviar malestar abdominal, dolor abdominal, calambres abdominales y alteraciones en el movimiento intestinal; en la medida en que estas condiciones y síntomas estén asociados con estrés.
MX2013007737A 2010-12-29 2011-12-28 Fibra y probioticos para reducir sintomas intestinales relacionados con estres. MX2013007737A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10197272 2010-12-29
EP11156435 2011-03-01
PCT/EP2011/074187 WO2012089782A1 (en) 2010-12-29 2011-12-28 Fiber and probiotics for reducing intestinal symptoms related to stress

Publications (1)

Publication Number Publication Date
MX2013007737A true MX2013007737A (es) 2013-07-24

Family

ID=45464569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007737A MX2013007737A (es) 2010-12-29 2011-12-28 Fibra y probioticos para reducir sintomas intestinales relacionados con estres.

Country Status (9)

Country Link
US (1) US20130280225A1 (es)
EP (1) EP2658559A1 (es)
CN (1) CN103415295A (es)
AU (1) AU2011351418A1 (es)
BR (1) BR112013017023A2 (es)
CL (1) CL2013001940A1 (es)
MX (1) MX2013007737A (es)
SG (1) SG191417A1 (es)
WO (1) WO2012089782A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149549A2 (en) 2011-04-29 2012-11-01 Auburn University Bacillus bacteria for use in treating and preventing infection in aquatic animals
WO2013126015A1 (en) * 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
GB201312713D0 (en) 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
WO2015086788A1 (en) * 2013-12-13 2015-06-18 Nestec S.A. Use of a sweet whey containing infant formula for promoting the postnatal neuronal development of the infant gastrointestinal tract, and the establishment of the intestinal functions that it controls
CA2947436A1 (en) * 2014-05-12 2015-11-19 BiOWiSH Technologies, Inc. Compositions and methods for improving human health and nutrition
GB2551642B (en) * 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
BR112018000934B1 (pt) * 2015-08-31 2022-02-01 Société des Produits Nestlé S.A. Usos de bifidobacterium longum para tratar ou prevenir sintomas depressivos
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
WO2019071193A1 (en) * 2017-10-05 2019-04-11 Ganeden Biotech, Inc. BACILLUS COAGULANS INACTIVATED AND USES FOR STRESS REDUCTION
JP2021518439A (ja) * 2018-03-22 2021-08-02 アデア ファーマシューティカルズ エスアーエス 微生物組成物の新たな使用
WO2019202033A1 (en) * 2018-04-18 2019-10-24 Danstar Ferment Ag Method for alleviating tobacco or nicotine withdrawal symptoms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68914401T2 (de) 1988-10-07 1994-08-25 Matsutani Kagaku Kogyo Kk Verfahren zur Herstellung von Dextrin enthaltenden faserigen Nahrungsprodukten.
US5358729A (en) 1991-08-28 1994-10-25 Matsutani Chemical Industries Co., Ltd. Indigestible dextrin
DE29724815U1 (de) 1997-01-09 2004-07-22 Société des Produits Nestlé S.A. Probiotik enthaltendes Getreideprodukt
ATE513551T1 (de) * 2003-01-24 2011-07-15 Flora Technology Inc Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
JP5473190B2 (ja) * 2003-10-16 2014-04-16 ネステク ソシエテ アノニム 化学療法又は放射線療法の副作用に対する栄養組成物
US20060115465A1 (en) * 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US20060240148A1 (en) * 2005-04-13 2006-10-26 The Dannon Company, Inc. High-fiber dairy product
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
WO2009102193A1 (en) * 2008-02-12 2009-08-20 N.V. Nutricia A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
US8137718B2 (en) * 2008-09-19 2012-03-20 Mead Johnson Nutrition Company Probiotic infant products
IT1392672B1 (it) * 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina

Also Published As

Publication number Publication date
CN103415295A (zh) 2013-11-27
EP2658559A1 (en) 2013-11-06
CL2013001940A1 (es) 2014-02-14
SG191417A1 (en) 2013-07-31
WO2012089782A1 (en) 2012-07-05
AU2011351418A1 (en) 2013-07-25
BR112013017023A2 (pt) 2019-09-24
US20130280225A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
MX2013007737A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres.
MX2013007735A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres cronico.
MX2013007736A (es) Una composicion nutricional que comprende fibra y probioticos para reducir sintomas intestinales relacionados con estres.
IN2012DN02463A (es)
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
WO2011110918A8 (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
MY189329A (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
MX2012005524A (es) Cepa de probioticos bifidobacterium.
TR201902529T4 (tr) Bağışıklığı etkileyen besin bileşimi.
IN2012DN01920A (es)
EP2395963A4 (en) IMPROVED EXERCISE ROLL
ZA201005834B (en) Linking visual properties of charts to cells withing tables
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
UA100551C2 (en) Synbiotic mixture
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
MX2012010427A (es) Cepas de levaduras y sus usos en la produccion de lipidos.
MY151104A (en) Novel use
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
EP2575833A4 (en) THERAPEUTIC AMOUNTS AND USES THEREOF
MX2011012071A (es) Prevencion y tratamiento de diarrea alergica.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
WO2011019867A3 (en) Dietary supplements and methods for treating pain and inflammation
MX345124B (es) Bacteria novedosa y estractos de la bacteria y el uso de la misma en terapia.
GB201107068D0 (en) Prebiotic agent
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal